Evidence Review GLP-1 receptor agonists are medications licensed in the UK for type 2 diabetes and obesity management
Marine Environmental Research, 183 , 105805
SGLT2i use was associated with a significantly increased risk of DKA (RR 2.08 [95% CI 1.05, 4.12] p =0.0309)
Plasma TMAO concentrations were observed to be increased with age in humans and mice (Li et al., 2018b
doi: 10.3389/fspor.2026.1819117 Received 27 February 2026 Revised 16 April 2026 Accepted 20 April 2026 Published 13 May 2026 Volume 8 - 2026 Edited by Simin Feng, Zhejiang University of Technology, China Reviewed by Andr Luis Shinohara, Faculdade de Odontologia da Universidade de So Paulo, Brazil Venkata Rajasekhar Kali, University of Hyderabad, India Updates Copyright 2026 Huang, Zhu, Zang, Chen, Chen, Xu and Liu
Zhou et al., 2024)